CNN: The questions eating disorder experts have about weight loss medications
The University of Cincinnati's Susan McElroy, MD, spoke with CNN about the impact weight loss medications like semaglutide have on people with eating disorders. McElroy's research focuses on eating disorders, bipolar disorder and the cooccurrence of psychiatric illness with obesity.
Semaglutide, sold under brand names like Ozempic and Wegovy, are a kind of drug called glucagon-like peptide-1 receptor agonists or GLP-1 agonists. While originally prescribed for diabetes, semaglutide is becoming more and more popular for weight loss.
McElroy said there is little research on the connection between eating disorders and weight loss medications.
“I view eating disorders as the last frontier in psychiatry,” said McElroy, the Linda and Harry Fath endowed professor in the Department of Psychiatry & Behavioral Neuroscience in UC’s College of Medicine and chief research officer at the Lindner Center of HOPE. “The eating disorder field is hard because we’re just ignored.”
In general, medications that cause weight loss have a good chance to also reduce binge eating, McElroy said, but there currently isn't enough research into how to treat disorders like binge eating disorder with these medications.
“We desperately need more compounds to treat people with eating disorders,” McElroy said.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.